Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
2(40%)
Results Posted
33%(1 trials)

Phase Distribution

Ph phase_2
2
40%
Ph phase_3
3
60%

Phase Distribution

0

Early Stage

2

Mid Stage

3

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
2(40.0%)
Phase 3Large-scale testing
3(60.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

5

all time

Status Distribution
Active(2)
Completed(3)

Detailed Status

Completed3
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
2
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 22 (40.0%)
Phase 33 (60.0%)

Trials by Status

completed360%
recruiting240%

Recent Activity

2 active trials
Showing 5 of 5
recruitingphase_3

A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy

NCT07363720
recruitingphase_2

A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions

NCT05816382
completedphase_3

A Study of TAK-861 in People With Narcolepsy Type 1

NCT06505031
completedphase_3

A Study of TAK-861 for the Treatment of Narcolepsy Type 1

NCT06470828
completedphase_2

A Study of TAK-861 in Participants With Narcolepsy Type 1

NCT05687903

Clinical Trials (5)

Showing 5 of 5 trials
NCT07363720Phase 3

A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy

Recruiting
NCT05816382Phase 2

A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions

Recruiting
NCT06505031Phase 3

A Study of TAK-861 in People With Narcolepsy Type 1

Completed
NCT06470828Phase 3

A Study of TAK-861 for the Treatment of Narcolepsy Type 1

Completed
NCT05687903Phase 2

A Study of TAK-861 in Participants With Narcolepsy Type 1

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5